Skip to main content
Premium Trial:

Request an Annual Quote

Jeffrey Jones

Isis Pharmaceuticals has appointed Jeffrey Jones as executive vice president.
In this position, Jones will lead clinical development, preclinical development, regulatory affairs, and quality assurance and compliance at Isis, the company said.
Prior to joining Isis, Jones held various positions at Forest Laboratories, most recently chief medical officer and executive vice president. Before working at Forest, he worked at Upjohn Laboratories as director of psychopharmacology and later chief medical officer and vice president of clinical development.
Jones received an MD from Harvard Medical School, Isis said.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.